Detalles de la búsqueda
1.
PillarX: A Microfluidic Device to Profile Circulating Tumor Cell Clusters Based on Geometry, Deformability, and Epithelial State.
Small
; 18(17): e2106097, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35344274
2.
Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials.
Oncologist
; 25(9): 780-786, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32272500
3.
The Landscape of Actionable Gene Fusions in Colorectal Cancer.
Int J Mol Sci
; 20(21)2019 Oct 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-31731495
4.
PillarX: A Microfluidic Device to Profile Circulating Tumor Cell Clusters Based on Geometry, Deformability, and Epithelial State.
Small
; 18(48): e2206567, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36453561
5.
Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities.
Crit Rev Oncol Hematol
; 190: 104109, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37643668
6.
Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison.
Clin Breast Cancer
; 23(3): e151-e162, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36599769
7.
The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis.
Ther Adv Med Oncol
; 15: 17588359231165978, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37063779
8.
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation.
J Clin Oncol
; 41(34): 5263-5273, 2023 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37535876
9.
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors.
NPJ Breast Cancer
; 9(1): 27, 2023 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37069173
10.
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors.
Ther Adv Med Oncol
; 15: 17588359231204857, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38130467
11.
Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications.
Ther Adv Med Oncol
; 14: 17588359221079123, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35281350
12.
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin.
Front Oncol
; 12: 925551, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36059635
13.
Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial.
Eur J Cancer
; 172: 300-310, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35810555
14.
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
Clin Lung Cancer
; 23(1): e17-e28, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34334296
15.
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.
Eur J Cancer
; 167: 142-148, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35307254
16.
Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center.
Ther Adv Med Oncol
; 14: 17588359221108687, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35923922
17.
Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape.
Cell Metab
; 33(11): 2247-2259.e6, 2021 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34731655
18.
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients.
Ther Adv Med Oncol
; 13: 17588359211006960, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33948122
19.
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer.
Cancer Lett
; 511: 77-87, 2021 07 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-33961924
20.
The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab.
Cancers (Basel)
; 13(8)2021 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33921727